All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 3 points (0.0%) at 17,053 as of Friday, Oct. 9, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,606 issues advancing vs. 1,356 declining with 155 unchanged.

The Health Care sector currently sits up 0.6% versus the S&P 500, which is up 1.7%. Top gainers within the sector include Centene ( CNC), up 3.6%, Medivation ( MDVN), up 3.5%, Anthem ( ANTM), up 2.2%, Eli Lilly and ( LLY), up 2.0% and Valeant Pharmaceuticals International ( VRX), up 1.8%. On the negative front, top decliners within the sector include Alexion Pharmaceuticals ( ALXN), down 2.3%, Celgene ( CELG), down 1.5%, Shire ( SHPG), down 1.3%, Novartis ( NVS), down 1.1% and Bristol-Myers Squibb Company ( BMY), down 1.1%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Illumina ( ILMN) is one of the companies pushing the Health Care sector higher today. As of noon trading, Illumina is up $5.34 (3.8%) to $145.71 on average volume. Thus far, 946,583 shares of Illumina exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $140.34-$147.07 after having opened the day at $141.28 as compared to the previous trading day's close of $140.37.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $21.1 billion and is part of the drugs industry. Shares are down 23.9% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts who rate Illumina a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Illumina Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Abbott Laboratories ( ABT) is up $0.64 (1.5%) to $41.80 on average volume. Thus far, 4.9 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.1 million shares. The stock has ranged in price between $40.94-$41.91 after having opened the day at $41.07 as compared to the previous trading day's close of $41.16.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abbott Laboratories manufactures and sells health care products worldwide. Abbott Laboratories has a market cap of $60.6 billion and is part of the health services industry. Shares are down 8.6% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Abbott Laboratories Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, UnitedHealth Group ( UNH) is up $1.82 (1.6%) to $117.90 on average volume. Thus far, 1.8 million shares of UnitedHealth Group exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $115.96-$118.92 after having opened the day at $116.02 as compared to the previous trading day's close of $116.08.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. UnitedHealth Group has a market cap of $111.0 billion and is part of the health services industry. Shares are up 14.8% year-to-date as of the close of trading on Thursday. Currently there are 17 analysts who rate UnitedHealth Group a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates UnitedHealth Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, increase in net income and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full UnitedHealth Group Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).